Natural, innate improvements in multiple sclerosis disability. (Q51187507)

1 April 2018

title

Natural, innate improvements in multiple sclerosis disability. (English)

1 reference

1 April 2018

0 references

1

1 reference

1 April 2018

author name string

Feng Zhu

2

1 reference

1 April 2018

John Petkau

3

1 reference

1 April 2018

Joel Oger

4

1 reference

1 April 2018

Yinshan Zhao

5

1 reference

1 April 2018

BC MS Clinic Neurologists

6

1 reference

1 April 2018

publication date

26 June 2012

1 reference

1 April 2018

Multiple Sclerosis Journal

published in

1 reference

1 April 2018

volume

18

1 reference

1 April 2018

issue

10

1 reference

1 April 2018

page(s)

1412-1421

1 reference

1 April 2018

Multiple sclerosis: diagnosis and the management of acute relapses

cites work

1 reference

https://api.crossref.org/works/10.1177%2F1352458512439119

Disability outcome measures in therapeutic trials of relapsing-remitting multiple sclerosis: effects of heterogeneity of disease course in placebo cohorts

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512439119

Disability as an outcome in MS clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512439119

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512439119

Alemtuzumab versus interferon β-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512439119

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512439119

Multiple sclerosis risk sharing scheme: two year results of clinical cohort study with historical comparator

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512439119

Disability progression in multiple sclerosis is slower than previously reported.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512439119

New perspectives in the natural history of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512439119

New diagnostic criteria for multiple sclerosis: guidelines for research protocols

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512439119

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512439119

Models for longitudinal data: a generalized estimating equation approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512439119

An overview of methods for the analysis of longitudinal data

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512439119

Defining the clinical course of multiple sclerosis: Results of an international survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512439119

Improvement in disability after alemtuzumab treatment of multiple sclerosis is associated with neuroprotective autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512439119

Enhancing remyelination in disease--can we wrap it up?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512439119

Interrater variability with the Expanded Disability Status Scale (EDSS) and Functional Systems (FS) in a multiple sclerosis clinical trial. The Canadian Cooperation MS Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512439119

Inter- and intrarater scoring agreement using grades 1.0 to 3.5 of the Kurtzke Expanded Disability Status Scale (EDSS). Multiple Sclerosis Collaborative Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512439119

Measuring patient-centered outcomes in neurologic disease. Extending the Q-TWiST method.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512439119

An assessment of disability rating scales used in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512439119

Observer disagreement in rating neurologic impairment in multiple sclerosis: facts and consequences.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512439119

The natural history of multiple sclerosis: a geographically based study. 5. The clinical features and natural history of primary progressive multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512439119

Establishment and use of multiple sclerosis registers--EDMUS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512439119

Primary progressive multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512439119

21 January 2018

Identifiers

DOI

10.1177/1352458512439119

1 reference

1 April 2018

1 reference

1 April 2018